Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aaron Seth Kesselheim, M.D.

Co-Author

This page shows the publications co-authored by Aaron Kesselheim and Ameet Sarpatwari.
Connection Strength

25.464
  1. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Netw Open. 2022 01 04; 5(1):e2144386.
    View in: PubMed
    Score: 0.979
  2. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. Health Aff (Millwood). 2021 05; 40(5):772-778.
    View in: PubMed
    Score: 0.934
  3. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Saf. 2021 Jul; 44(7):743-751.
    View in: PubMed
    Score: 0.933
  4. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges. J Law Med Ethics. 2021; 49(1):6-9.
    View in: PubMed
    Score: 0.913
  5. Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Saf. 2021 Mar; 44(3):327-335.
    View in: PubMed
    Score: 0.906
  6. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation? BMJ. 2020 10 08; 371:m3841.
    View in: PubMed
    Score: 0.898
  7. Missed Opportunities on Emergency Remdesivir Use. JAMA. 2020 07 28; 324(4):331-332.
    View in: PubMed
    Score: 0.886
  8. Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support. Ann Intern Med. 2020 03 03; 172(5):348-350.
    View in: PubMed
    Score: 0.856
  9. Reforming the Orphan Drug Act for the 21st Century. N Engl J Med. 2019 Jul 11; 381(2):106-108.
    View in: PubMed
    Score: 0.824
  10. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. J Gen Intern Med. 2019 03; 34(3):420-428.
    View in: PubMed
    Score: 0.796
  11. The US Biosimilar Market: Stunted Growth and Possible Reforms. Clin Pharmacol Ther. 2019 01; 105(1):92-100.
    View in: PubMed
    Score: 0.794
  12. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374.
    View in: PubMed
    Score: 0.766
  13. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Aff (Millwood). 2018 05; 37(5):732-737.
    View in: PubMed
    Score: 0.759
  14. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clin Pharmacol Ther. 2018 06; 103(6):1093-1099.
    View in: PubMed
    Score: 0.736
  15. Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Saf. 2017 02; 40(2):105-108.
    View in: PubMed
    Score: 0.696
  16. Factors Influencing Prescription Drug Costs in the United States-Reply. JAMA. 2016 12 13; 316(22):2431-2432.
    View in: PubMed
    Score: 0.690
  17. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30; 316(8):858-71.
    View in: PubMed
    Score: 0.672
  18. Navigating the Dermatological Drug Cost Curve. JAMA. 2016 Jun 28; 315(24):2724-5.
    View in: PubMed
    Score: 0.668
  19. State Initiatives to Control Medication Costs--Can Transparency Legislation Help? N Engl J Med. 2016 Jun 16; 374(24):2301-4.
    View in: PubMed
    Score: 0.666
  20. Efficacy of the Priority Review Voucher Program. JAMA. 2016 Apr 19; 315(15):1660-1.
    View in: PubMed
    Score: 0.659
  21. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? PLoS Med. 2016 Feb; 13(2):e1001955.
    View in: PubMed
    Score: 0.650
  22. Experience With the Priority Review Voucher Program for Drug Development. JAMA. 2015 Oct 27; 314(16):1687-8.
    View in: PubMed
    Score: 0.638
  23. The 21st century cures act: Opportunities and challenges. Clin Pharmacol Ther. 2015 Dec; 98(6):575-7.
    View in: PubMed
    Score: 0.635
  24. Progress and Hurdles for Follow-on Biologics. N Engl J Med. 2015 Jun 18; 372(25):2380-2.
    View in: PubMed
    Score: 0.617
  25. Expanded access to investigational drugs. N Engl J Med. 2015 04 09; 372(15):1473-4.
    View in: PubMed
    Score: 0.614
  26. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802.
    View in: PubMed
    Score: 0.611
  27. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. Clin Pharmacol Ther. 2015 Feb; 97(2):186-93.
    View in: PubMed
    Score: 0.601
  28. Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17; 370(16):1476-8.
    View in: PubMed
    Score: 0.573
  29. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. Health Aff (Millwood). 2021 08; 40(8):1198-1205.
    View in: PubMed
    Score: 0.238
  30. Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clin Pharmacol Ther. 2021 10; 110(4):1050-1056.
    View in: PubMed
    Score: 0.236
  31. Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. JAMA Intern Med. 2021 07 01; 181(7):995-997.
    View in: PubMed
    Score: 0.236
  32. Generic Competition for Drugs Treating Rare Diseases. J Law Med Ethics. 2020 12; 48(4):789-795.
    View in: PubMed
    Score: 0.227
  33. Clinical Development Times for Biosimilars in the United States. Mayo Clin Proc. 2020 10; 95(10):2152-2154.
    View in: PubMed
    Score: 0.224
  34. Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020 12; 108(6):1308-1314.
    View in: PubMed
    Score: 0.222
  35. Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. Am J Manag Care. 2020 08; 26(8):340-347.
    View in: PubMed
    Score: 0.222
  36. Novelty of Active Ingredients in High-Cost Brand-Name Drugs. J Gen Intern Med. 2020 07; 35(7):2219-2221.
    View in: PubMed
    Score: 0.213
  37. Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study. Ann Intern Med. 2019 11 05; 171(9):605-611.
    View in: PubMed
    Score: 0.209
  38. The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Aff (Millwood). 2019 07; 38(7):1182-1187.
    View in: PubMed
    Score: 0.206
  39. Orphan Drug Designation and Exclusivity for "Same Drugs". J Law Med Ethics. 2019 06; 47(2):347-349.
    View in: PubMed
    Score: 0.204
  40. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20; 379(12):1097-1099.
    View in: PubMed
    Score: 0.195
  41. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 11 01; 177(11):1665-1669.
    View in: PubMed
    Score: 0.183
  42. Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017 08 15; 318(7):609-610.
    View in: PubMed
    Score: 0.181
  43. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One. 2017; 12(4):e0175313.
    View in: PubMed
    Score: 0.176
  44. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Aff (Millwood). 2017 02 01; 36(2):362-370.
    View in: PubMed
    Score: 0.174
  45. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Drug Saf. 2016 08; 39(8):709-14.
    View in: PubMed
    Score: 0.168
  46. Regulatory Solutions to the Problem of High Generic Drug Costs. Open Forum Infect Dis. 2015 Dec; 2(4):ofv179.
    View in: PubMed
    Score: 0.160
  47. Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med. 2015 Sep 03; 373(10):967-73.
    View in: PubMed
    Score: 0.158
  48. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015 Jan 15; 372(3):279-86.
    View in: PubMed
    Score: 0.151
  49. Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9.
    View in: PubMed
    Score: 0.149
  50. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany. Health Aff (Millwood). 2020 07; 39(7):1185-1193.
    View in: PubMed
    Score: 0.055
  51. Correction to: FDA and EMA Biosimilar Approvals. J Gen Intern Med. 2019 Dec 05.
    View in: PubMed
    Score: 0.053
  52. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. J Gen Intern Med. 2019 11; 34(11):2339-2341.
    View in: PubMed
    Score: 0.053
  53. FDA and EMA Biosimilar Approvals. J Gen Intern Med. 2020 06; 35(6):1908-1910.
    View in: PubMed
    Score: 0.053
  54. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019 03; 16(3):e1002763.
    View in: PubMed
    Score: 0.050
  55. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2019 01; 42(1):85-93.
    View in: PubMed
    Score: 0.050
  56. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018 Apr 03; 361:k1180.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.